Duchenne muscular dystrophy.

Article Details

Citation

Yiu EM, Kornberg AJ

Duchenne muscular dystrophy.

Neurol India. 2008 Jul-Sep;56(3):236-47. doi: 10.4103/0028-3886.43441.

PubMed ID
18974549 [ View in PubMed
]
Abstract

Duchenne muscular dystrophy (DMD), an X-linked disorder, is the most common muscular dystrophy in children, presenting in early childhood and characterized by proximal muscle weakness and calf hypertrophy in affected boys. Patients usually become wheelchair-bound by the age of 12 years, and die of cardiorespiratory complications in their late teens to early twenties. Advances in the management of DMD, including treatment with corticosteroids and the use of intermittent positive pressure ventilation have provided improvements in function, ambulation, quality of life and life expectancy, although novel therapies still aim to provide a cure for this devastating disorder. The clinical features, investigations, and management of DMD are reviewed, as well as the latest in some of the novel therapies.

DrugBank Data that Cites this Article

Drugs